IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease
Copyright © 2022 Versace, Bitto, Ioppolo, Aragona, La Rosa, Roberts, D'Angelo, Cinquegrani, Cirmi, Irrera, Navarra, Corrao, Gangemi and Bagnato..
OBJECTIVE: Systemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis. Our aim was to test whether both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared to SSc patients without ILD and healthy controls.
METHODS: Serum levels of IL-13 and IL-33 were measured in 30 SSc patients with diffuse disease and 30 healthy controls by enzyme-linked immunosorbent assay. The extent of pulmonary fibrosis was assessed according to HRCT Warrick score. Pulmonary function tests included lung diffusion capacity for carbon monoxide, forced vital capacity and total lung capacity.
RESULTS: Both IL-13 and IL-33 levels were increased in SSc patients compared to controls and significantly associated each other. DLco, FVC and TLC scores were inversely associated with IL-33 and IL-13 levels. Both IL-33 and IL-13 levels were significantly associated with the Warrick severity score and higher in the group of SSc patients with reduced pulmonary function compared to SSc patients with normal pulmonary function tests.
CONCLUSION: The IL-13/IL-33 axis needs to be further explored in longitudinal studies of SSc-ILD patients to assess its validity as a biomarker and future treatment target, as does downstream mediator ST2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Frontiers in medicine - 9(2022) vom: 26., Seite 825567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Versace, Antonio Giovanni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
IL-13 |
|---|
| Anmerkungen: |
Date Revised 02.05.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmed.2022.825567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337833222 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337833222 | ||
| 003 | DE-627 | ||
| 005 | 20231225235321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2022.825567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337833222 | ||
| 035 | |a (NLM)35252259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Versace, Antonio Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.05.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Versace, Bitto, Ioppolo, Aragona, La Rosa, Roberts, D'Angelo, Cinquegrani, Cirmi, Irrera, Navarra, Corrao, Gangemi and Bagnato. | ||
| 520 | |a OBJECTIVE: Systemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis. Our aim was to test whether both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared to SSc patients without ILD and healthy controls | ||
| 520 | |a METHODS: Serum levels of IL-13 and IL-33 were measured in 30 SSc patients with diffuse disease and 30 healthy controls by enzyme-linked immunosorbent assay. The extent of pulmonary fibrosis was assessed according to HRCT Warrick score. Pulmonary function tests included lung diffusion capacity for carbon monoxide, forced vital capacity and total lung capacity | ||
| 520 | |a RESULTS: Both IL-13 and IL-33 levels were increased in SSc patients compared to controls and significantly associated each other. DLco, FVC and TLC scores were inversely associated with IL-33 and IL-13 levels. Both IL-33 and IL-13 levels were significantly associated with the Warrick severity score and higher in the group of SSc patients with reduced pulmonary function compared to SSc patients with normal pulmonary function tests | ||
| 520 | |a CONCLUSION: The IL-13/IL-33 axis needs to be further explored in longitudinal studies of SSc-ILD patients to assess its validity as a biomarker and future treatment target, as does downstream mediator ST2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IL-13 | |
| 650 | 4 | |a IL-33 | |
| 650 | 4 | |a interleukins | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a systemic sclerosis | |
| 700 | 1 | |a Bitto, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Ioppolo, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Aragona, Caterina Oriana |e verfasserin |4 aut | |
| 700 | 1 | |a La Rosa, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, William Neal |e verfasserin |4 aut | |
| 700 | 1 | |a D'Angelo, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Cinquegrani, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Cirmi, Santa |e verfasserin |4 aut | |
| 700 | 1 | |a Irrera, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Navarra, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Corrao, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Gangemi, Sebastiano |e verfasserin |4 aut | |
| 700 | 1 | |a Bagnato, Gianluca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 9(2022) vom: 26., Seite 825567 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g day:26 |g pages:825567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2022.825567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |b 26 |h 825567 | ||